focus -WSS

focus

author：entertainment 2025-10-01 18:35:25 - browse：8224

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Weight loss drugs should be covered by insurers, AMA says

focus

Wikipedia

WSS

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

How to bring more disabled researchers into academia

The problem with charging patients to message their doctors

First medicine developed to treat MASH expected to be approved soon

Just how do doctors, lawmakers, and the public define abortion?

First transplant of an entire human eye performed

hotspot

focus

focus

The high cost of giving birth even with insurance

What health policies could hitch a ride on a spending bill?

Supreme Court strikes down use of affirmative action

How to bring more disabled researchers into academia

Medical leaders decry Supreme Court decision on affirmative action

Air quality improving but still lags in Black, Hispanic communities

Anesthesiologist group: stop taking Ozempic before surgery

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Medical records are filled with copy

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Wikipedia

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

In his State of the Union, Biden takes clear aim at 'Big Pharma'

With psoriasis trial ahead, Alumis raises $259 million

The problem with charging patients to message their doctors

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

focus

hotspot

Wikipedia

entertainment